BioArctic Logo

BioArctic

Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.

BIOA | ST

Overview

Corporate Details

ISIN(s):
SE0010323303 (+1 more)
LEI:
549300Y0OI2WVUNHLC33
Country:
Sweden
Address:
Warfvinges väg 35, 112 51 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:15
Regulatory News Service
Kina godkänner intravenös underhållsbehandling med Leqembi®
Swedish 235.6 KB
2025-09-29 08:15
Regulatory News Service
Leqembi® approved for IV maintenance treatment in China
English 229.9 KB
2025-09-24 08:40
Regulatory News Service
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
English 237.4 KB
2025-09-24 08:40
Regulatory News Service
Australien godkänner Leqembi® för behandling av tidig Alzheimers sjukdom
Swedish 225.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
Swedish 182.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctic’s founders intend to divest minor part of their shareholding
English 179.0 KB
2025-09-03 01:30
Regulatory News Service
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as …
English 211.3 KB
2025-09-03 01:30
Regulatory News Service
Stegvis ansökningsprocess påbörjad för marknadsgodkännande i USA av Leqembi® Iq…
Swedish 253.3 KB
2025-09-01 18:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
English 196.1 KB
2025-09-01 18:30
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 29 augusti 2025
Swedish 209.2 KB
2025-08-29 23:56
Regulatory News Service
Amerikanska läkemedelsverket godkänner subkutan underhållsbehandling med Leqemb…
Swedish 251.3 KB
2025-08-29 23:55
Regulatory News Service
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for m…
English 212.0 KB
2025-08-28 08:00
Interim Report
Swedish 1.8 MB
2025-08-28 08:00
Interim Report
English 1.6 MB
2025-08-26 07:05
M&A Activity
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar B…
Swedish 201.1 KB

Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioArctic via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-13 Gunilla Osswald Other Sell 40,000 8,821,200.00 SEK
2025-02-13 Gunilla Osswald Other Other 40,000 3,344,000.00 SEK
2025-02-13 Sten Mikael Moge Other Sell 6,000 1,323,180.00 SEK
2025-02-13 Sten Mikael Moge Other Other 6,000 501,600.00 SEK
2025-02-13 Johanna Margareta Fälting Other Sell 1,500 330,795.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 2,500 209,000.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 1,500 125,400.00 SEK
2025-01-10 Mikael Smedeby Other Buy 730 148,920.00 SEK
2024-12-19 Oskar Bosson Other Sell 2,000 446,000.00 SEK
2024-12-19 Oskar Bosson Other Sell 871 195,626.60 SEK

Peer Companies

Company Country Ticker View
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR
Puretech Health PLC Logo
A clinical-stage biotherapeutics company developing new medicines for devastating diseases.
United States of America PRTC
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland CRM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France ALQGC
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea 348080
Recordati Industria Chimica e Farmaceutica Logo
Global pharma group developing drugs for common/rare diseases & supplying APIs worldwide.
Italy REC
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel REKA
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden RESP

Talk to a Data Expert

Have a question? We'll get back to you promptly.